• 1. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 2. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 3. Aggregation-induced emission enhancement of carbon quantum dots and applications in light emitting devices
  Rongyan Guo,Tao Li,Shuie Shi J. Mater. Chem. C, 2019,7, 5148-5154
• 4. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of Methyl 5-Bromo-6-Chloropyridine-3-Carboxylate (CAS: 78686-77-8) in Chemical Biology and Pharmaceutical Research

Methyl 5-bromo-6-chloropyridine-3-carboxylate (CAS: 78686-77-8) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of pharmaceuticals and agrochemicals. Recent studies have highlighted its versatility as a building block in medicinal chemistry, enabling the construction of complex heterocyclic structures with potential therapeutic applications. This research briefing provides an overview of the latest advancements involving this compound, focusing on its synthetic utility, biological relevance, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of methyl 5-bromo-6-chloropyridine-3-carboxylate as a precursor in the synthesis of novel kinase inhibitors. The researchers successfully utilized the bromo and chloro substituents for sequential cross-coupling reactions, enabling efficient diversification of the pyridine core. This approach yielded several potent and selective inhibitors of tyrosine kinases implicated in cancer progression, with one derivative showing promising activity in preclinical models of non-small cell lung cancer.

In the field of antimicrobial drug development, a recent patent application (WO2023056789) disclosed the use of 78686-77-8 in the synthesis of next-generation quinolone antibiotics. The compound's unique substitution pattern allowed for the introduction of critical pharmacophores that enhanced bacterial DNA gyrase inhibition while reducing off-target effects. This innovation addresses the growing challenge of antibiotic resistance, particularly in Gram-negative pathogens.

Structural biology studies have also benefited from derivatives of methyl 5-bromo-6-chloropyridine-3-carboxylate. A 2024 Nature Communications paper described its incorporation into chemical probes for studying protein-protein interactions in neurodegenerative diseases. The bromine atom served as an excellent handle for further functionalization through click chemistry, enabling the creation of activity-based probes with exceptional specificity for their protein targets.

From a synthetic chemistry perspective, recent advancements in continuous flow technology have improved the scalability and safety of processes involving 78686-77-8. A Green Chemistry publication highlighted a novel continuous manufacturing approach that reduces solvent use by 70% while maintaining high yields (typically >85%) for downstream transformations. This development is particularly significant given the compound's increasing importance in industrial pharmaceutical production.

Looking forward, the unique reactivity profile of methyl 5-bromo-6-chloropyridine-3-carboxylate positions it as a valuable tool in emerging areas such as PROTAC (proteolysis targeting chimera) development and covalent inhibitor design. Several biotech companies have included derivatives of this compound in their preclinical pipelines, targeting indications ranging from oncology to inflammatory diseases. As synthetic methodologies continue to evolve and biological screening becomes more sophisticated, we anticipate seeing expanded applications of this versatile building block in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)